INTRODUCTION
============

Peanut allergy is often severe and children seldom outgrow it. Its prevalence in Singapore among school-going children is 0.5%--0.6% \[[@B1]\], it accounts for 42% of the auto-injector prescriptions and it increasingly represents the top cause of anaphylaxis presenting to Paediatric Emergency Departments \[[@B2]\]. Strict avoidance is ideal, but challenging as peanut is ubiquitous in Asian cuisine. Half of our children with peanut allergy report accidental ingestion after their diagnosis, with a short median time to first accidental ingestion of 4 months and half of those accidental ingestions leading to reactions more severe than the first time \[[@B3]\].

The only study done in an Asian context is the pilot study done in Hong Kong which included omalizumab \[[@B4]\]. Omalizumab, due to the subcutaneous route of administration, is less desirable for use in young children. Hence, more evidence is needed on the efficacy and safety of peanut oral immunotherapy (OIT) in the Asian setting before it can be considered for clinical use.

We sought to assess the efficacy and safety of peanut OIT in children in Singapore.

MATERIALS AND METHODS
=====================

We did a pilot open-label study in Singaporean children, with 2 weekly dose escalation and maintenance phase lasting 12 months. Primary outcome was efficacy, assessed by oral food challenge (OFC) at 6 months into the maintenance phase and at 4 weeks after discontinuation of peanut OIT after having completed 12 months of maintenance therapy. Safety was assessed by symptom diaries.

Study population
----------------

Children aged 4 to 18 years, with peanut allergy (as defined below), were recruited from the Allergy Outpatient Clinic, Department of Paediatrics, National University Hospital, Singapore.

1.  \(1\) Positive food challenge to peanut in the last 1 year OR

2.  \(2\) Convincing reaction to peanut, AND one of the following: (a) a positive skin prick test (SPT) \> 3 mm, (b) specific IgE to peanuts \> 15 kU/L, or (c) specific IgE \> 7 kU/L with a history of a recent reaction to peanut within the past 6 months

They were excluded if they had history of anaphylaxis, presence of severe or uncontrolled asthma (defined as previous intensive care unit admissions/intubations, or increasing doses of inhaled corticosteroids needed to control asthma, or peak expiratory flow/spirometry values less than 70% of normal), comorbidities which could preclude them from undergoing an OFC, current use of medications which may interfere with treatment of a severe reaction, or inability to comply with the desensitisation protocol.

Schedule
--------

At visit 1, all subjects underwent a baseline OFC to peanut protein in the form of partially defatted peanut flour (12% fat light roast; Golden Peanut Co., Alpharetta, GA, USA; 2-g flour = 1-g peanut protein). The dose steps (in peanut protein dose) were: 0.5, 1, 2, 5, 12, 25, 50, 100, 200, 400, 800, 1,600, 3,000. The interval between doses was 2 weeks, and the doses were increased until the maintenance dose of 3,000-mg peanut protein was reached. The first OFC was at 6 months into the maintenance phase (visit 2). After completion of treatment, subjects reverted to strict peanut avoidance for 4 weeks and then attended visit 3 to undergo second OFC ([Fig. 1](#F1){ref-type="fig"}).

![Schedule of oral immunotherapy. OFC, oral food challenge; QOL, quality of life.](apa-9-e1-g001){#F1}

All subjects also took daily intake of 2 × 10^10^ *Lactobacillus rhamnosus* GG (ATCC 53103) as an adjuvant during the maintenance phase. This recommendation follows the findings of improved efficacy and possible sustained unresponsiveness in a peanut OIT schedule which included *Lactobacillus rhamnosus* GG as an adjuvant \[[@B5]\].

Outcome measures
----------------

The primary outcomes were efficacy and safety.

### Efficacy

Efficacy was assessed by desensitisation, defined as percentage of subjects who passed the OFCs to 6,000-mg peanut protein at 6 months into maintenance therapy. Sustained unresponsiveness was defined as percentage of subjects who passed the second OFC to 6,000-mg peanut protein at visit 3.

### Safety

Safety was assessed with symptom diaries reviewed at each 2 weekly visit to the hospital. All adverse events reported by subjects were categorized into 6 systems as; skin, oral, upper respiratory tract, lower respiratory tract, gastrointestinal and cardiovascular, and classified as mild, moderate or severe. Skin manifestations include rash and angioedema, upper respiratory tract symptoms include rhinitis and cough, lower respiratory tract symptom refers to wheeze, gastrointestinal symptoms include abdominal pain and vomiting, and cardiovascular symptoms include palpitations and dizziness. Participants were withdrawn in the case of anaphylaxis.

Secondary outcomes were immunological parameters and quality of life (QoL).

Immunological parameters
------------------------

Major peanut allergen-specific IgE and IgG~4~ levels were measured in the subjects\' plasma samples using ImmunoCAP 100 instrument (Phadia AB, Uppsala, Sweden) according to the manufacturer\'s instructions. These included peanut extract, Ara h 1, Ara h 2, Ara h 3, Ara h 8 and Ara h 9. Blood was taken for these at baseline before starting peanut OIT (visit 1), 2 weeks after tolerating maintenance therapy (visit 2) and 4 weeks after discontinuation of peanut OIT (visit 3). SPTs (Greer Lab, Allergy Management) (SPTs) to peanut were also performed at these 3 visits.

Quality of life assessments
---------------------------

At the same 3 visits, QoL was assessed using age-specific and validated QoL questionnaires: Food Allergy Quality of Life Questionnaire -- Parent Form (FAQLQ-PF) for parents of children aged below 12 years of age, Food Allergy Quality of Life Questionnaire -- Child Form (FAQLQ-CF) for children aged 8--12 years, and Food Allergy Quality of Life Questionnaire -- Teenager Form (FAQLQ-TF) for adolescents aged 13--17 years \[[@B6][@B7][@B8]\]. These were scored out of a total of 6 for FAQLQ-PF and CF, and out of 7 for FAQLQ-TF.

Ethical considerations
----------------------

Ethical approval was granted by the Domain Specific Review Board, National Healthcare Group number 2013/00672. Informed consent was sought from all parents, with assent from the children as appropriate.

RESULTS
=======

Baseline characteristics
------------------------

Sixty-eight patients were screened for recruitment, of which, 11 were eligible. Two declined to participate hence 9 patients were recruited between December 2013 and January 2015. The median age of the patients was 8 years (range, 8--14 years); 2 were female. There were 3 Chinese patients, 2 Eurasian, and 4 Caucasian. The median baseline SPT wheal size to peanut extract was 15 mm (range, 8--25 mm), and specific IgE to peanut was 29.35 kU~A~/L for 4 patients and above the laboratory upper limit of measurement (\>100 kU~A~/L) for 5 patients. Five patients had concomitant food allergies or other atopic diseases. The other food allergies included egg, seafood and garlic. The median starting dose of peanut protein for OIT was 5 mg (range, 0.5--50 mg) ([Table 1](#T1){ref-type="table"}).

###### Subject characteristics and challenge outcomes

![](apa-9-e1-i001)

  Subject No.   Age at starting (yr)   Sex   Baseline skin prick test wheal (mm) to peanut   Latest peanut sIgE prior to enrolment (kU~A~/L)   Comorbidities                  Starting dose of peanut protein (mg)   Peanut protein (mg) tolerated, first challenge   Peanut protein (mg) tolerated, abstention for 4 weeks prior to second challenge
  ------------- ---------------------- ----- ----------------------------------------------- ------------------------------------------------- ------------------------------ -------------------------------------- ------------------------------------------------ ---------------------------------------------------------------------------------
  1             8                      M     20                                              28.7                                              Other food allergies, asthma   0.5                                    6,000                                            6,000
  2             8                      M     20                                              72.6                                              Other food allergies, eczema   0.5                                    6,000                                            \-
  3             14                     F     9                                               26.3                                              Asthma, allergic rhinitis      12                                     6,000                                            3,690
  4             7                      M     10                                              30                                                Other food allergies, asthma   0.5                                    3,000^\*^                                        \-
  5             8                      M     25                                              \>100                                             Nil                            5                                      Withdrawn                                        Withdrawn
  6             6                      M     15                                              \>100                                             Nil                            1                                      6,000                                            \-
  7             7                      F     8                                               \>100                                             Other food allergy, asthma     5                                      Withdrawn                                        Withdrawn
  8             10                     M     15                                              \>100                                             Asthma                         5                                      6,000                                            \-
  9             10                     M     11                                              \>100                                             Nil                            50                                     6,000                                            267
  Median        \-                     \-    15                                              29.35                                             \-                             5                                      \-                                               \-

^\*^Subject was afraid of ingesting more than 3,000 mg of protein.

Primary outcomes: efficacy
--------------------------

Seven of the 9 patients completed the OIT protocol. One subject withdrew almost immediately after enrolment due to noncompliance, and the other subject withdrew soon after the start of the maintenance phase due to the amount of psychological burden the child suffered from ingesting peanuts. The proportion of missed doses was 0.26%.

Of the 7 who completed OIT, 6 tolerated 6,000 mg of peanut protein at the first OFC at 6 months of maintenance phase; the last patient was afraid of consuming more than 3,000 mg of peanut protein but passed the challenge with 3,000 mg. After 12 months of maintenance therapy, only 3 of the 7 subjects consented to 4 weeks of abstinence. Of these, only 1 passed the challenge with 6,000 mg of peanut protein. The threshold of peanut protein tolerated decreased from 6,000 mg at first OFC to 3,690 mg for subject 3, and from 6,000 mg to 257 mg for subject 9 ([Table 1](#T1){ref-type="table"}).

Primary outcomes: safety
------------------------

The median frequency of side effects was 12% (range, 2.9%--28.5%) out of all doses taken during the updosing phase which decreased to 1.65% (range, 0%--18.8%) during the maintenance phase. The most frequent side effects involve the gastrointestinal system (65.7% of all side effects during updosing phase and 47.9% during maintenance phase), especially transient abdominal cramps, followed by skin in the form of urticarial or itch ([Fig. 2](#F2){ref-type="fig"}). Less frequent were upper respiratory, lower respiratory, oral and eye-related. Skin manifestations include rash and angioedema, upper respiratory tract symptoms include rhinitis and cough, lower respiratory tract symptom refers to wheeze, gastrointestinal symptoms include abdominal pain and vomiting, and cardiovascular symptoms include palpitations and dizziness. All side effects were mild, with no incident of anaphylaxis attributable to peanut OIT during treatment.

![Frequency of attributable side effects classified by system affected.](apa-9-e1-g002){#F2}

Side effects occurred more frequently during the first week after an updosing compared to the second week (58% reduction, *p* \< 0.05). They were also most commonly associated with intercurrent illness. Other contributory factors included lack of sleep, missing the previous daily dose, taking a hot bath just before ingestion of the daily dose and in 1 instance, just after an episode of anaphylaxis due to accidental ingestion of another food that the subject was known to be allergic to.

Secondary outcomes: immunological parameters
--------------------------------------------

There was a significant change in the median SPT wheal size to peanut extract, from 13 mm at baseline to 4 mm at visit 2 (*p* \< 0.05), and 5 mm at visit 3 (*p* \< 0.05).

There was a trend towards lower specific IgE to peanut extract, Ara h 1, Ara h 2, and Ara h 3 between visits 1 and 3 ([Fig. 3](#F3){ref-type="fig"}). There were no differences in specific IgE to Ara h 8 and Ara h 9 (data not shown).

![Specific IgE and specific IgG4 levels at visits 1, 2, and 3. Visit 1, baseline before starting peanut oral immunotherapy (OIT); visit 2, 6 weeks into maintenance therapy; visit 3, 4 weeks after discontinuation of peanut OIT.](apa-9-e1-g003){#F3}

There was an increase of peanut extract, Ara h 1, Ara h 2, and Ara h 3-specific IgG~4~ in the subjects\' plasma from visit 1 to visit 2 (*p* \< 0.05), but not between visits 2 and 3. There were no differences in Ara h 8 and Ara h 9-specific IgG~4~ between all visits (data not shown).

Secondary outcomes: QoL
-----------------------

Seven parents of children aged below 12 years completed the FAQLQ-PF at baseline and visit 2, and 5 at visit 3 (one withdrew and one was lost to follow up). Five children between 8 to 12 years of age completed the FAQLQ-CF and one 14-year-old patient completed the FAQLQ-TF at all 3 visits. The median baseline scores were 3.8, 4.1, and 7 out of a maximal possible 7 for PF, CF, and TF respectively.

At the end of OIT at visit 3, there was a trend towards improving QoL scores, with FAQLQ-PF scores decreasing by 0.5 (n = 5), FAQLQ-CF scores increasing by 0.1 (n = 5) and FAQLQ-TF score decreasing by 0.6 (n = 1).

Follow-up
---------

The patients were followed up for 2--3 years after the end of their peanut OIT. Of the 5 patients who were still in contact with the study team at the time of manuscript preparation, 4 were still consuming peanuts regularly at a dose that was acceptable to the child.

DISCUSSION
==========

This pilot study done in small cohort of children with peanut allergy, OIT was found to be efficacious and safe. The main side effects, gastrointestinal, followed by skin- and respiratory tract-related, were similar to previous studies \[[@B4], [@B5], [@B9]\].

Sustained unresponsiveness of 82%, as defined by discontinuation of therapy for a median of 2--3 weeks after completion of OIT, has been reported \[[@B5]\]. Of our 3 patients who consented to abstinence from peanut for 4 weeks after completion of OIT, only one child could tolerate 6 g of peanut protein upon rechallenge. When that child attempted to continue taking peanut at a frequency of once a month, mild symptoms reappeared by the next intake after the rechallenge, and persisted until the child increased the frequency of peanut intake to at least once a week. This supports the concept that tolerance does wear off over time even if there initially appears to be sustained unresponsiveness \[[@B10]\].

The withdrawal rate (2 out of 9 patients) in our cohort was similar to other studies, but instead of being directly related to the number of side effects these patients experienced, they were due to noncompliance and psychological burden. This highlights the importance of patient selection in the decision to embark on OIT for any food allergy.

Our baseline FAQLQ scores were higher than reported in other papers, reflective of greater impairment of QoL associated with peanut allergy \[[@B11]\]; this could be associated with the prevalence of peanut as an ingredient in Asian cooking, as well as lack of comprehensive food labelling. There was a general trend towards an improvement in QoL at the end of peanut OIT, but this was not statistically significant, likely due to the small sample size. In addition, a longer follow-up time would have been ideal, since it is reported that the QoL continues to improve 3 and 12 months after peanut OIT \[[@B11]\].

The small sample size limited our power to perform statistical analyses. However, the longitudinal nature of the study is its main strength, despite being pilot study with small sample size.

In conclusion, OIT for peanut allergy appears to be safe and effective in children in Singapore. Children who have completed peanut OIT should diligently continue to consume peanut as sustained unresponsiveness was not typical.
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